Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

26.49 +0.34 (+1.30%)

Streaming Delayed Price Updated: 12:05 PM EST, Jan 6, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	361,032
Open	26.50
Bid (Size)	26.47 (100)
Ask (Size)	26.50 (200)
Prev. Close	26.15
Today's Range	26.36 - 26.94
52wk Range	13.40 - 28.35
Shares Outstanding	162,625,379
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Rhythm Pharmaceuticals Faces Gravity: FDA Delays and Valuation Pressures Cool 2025’s Biotech Darling

December 30, 2025

As the final trading days of 2025 wind down, Rhythm Pharmaceuticals (Nasdaq: RYTM) finds itself at a critical crossroads. After a meteoric rise that saw the stock gain over 100% through the first three...

Via MarketMinute

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Shows Strong Growth Momentum and Technical Setup for Breakout ↗

December 25, 2025

ACADIA Pharmaceuticals shows strong earnings momentum and a bullish technical setup, presenting a potential breakout opportunity for growth investors.

Via Chartmill

Performance

YTD	+0.8%	+0.8%
1 Month	-1.0%	-1.0%
3 Month	+22.7%	+22.7%
6 Month	+26.9%	+26.9%
1 Year	+51.7%	+51.7%

More News

Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026

December 18, 2025

From Acadia Pharmaceuticals Inc.

Via Business Wire

Earnings Scheduled For November 5, 2025 ↗

November 05, 2025

Via Benzinga

Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome

December 12, 2025

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound? ↗

December 03, 2025

Via The Motley Fool

Healthcare Investor Exits $13 Million Stake STAAR Surgical Stake as Alcon Deal Drama Looms ↗

December 03, 2025

Via The Motley Fool

PTC Therapeutics Swings to a Profit on $211 Million in Revenue — Is This Why a Major Fund Just Invested $32 Million? ↗

December 03, 2025

Via The Motley Fool

Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares? ↗

December 03, 2025

Via The Motley Fool

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Shows Strong Growth Momentum and Technical Setup ↗

November 24, 2025

Via Chartmill

Why Dyne Therapeutics Stock Was Crushing it This Week ↗

November 21, 2025

Via The Motley Fool

Acadia Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference

November 20, 2025

From Acadia Pharmaceuticals Inc.

Via Business Wire

Beyond The Numbers: 6 Analysts Discuss ACADIA Pharmaceuticals Stock ↗

November 06, 2025

Via Benzinga

Acadia (ACAD) Q3 2025 Earnings Call Transcript ↗

November 05, 2025

Via The Motley Fool

Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview

November 05, 2025

From Acadia Pharmaceuticals Inc.

Via Business Wire

ACADIA Pharmaceuticals's Earnings: A Preview ↗

November 04, 2025

Via Benzinga

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Presents a Compelling Growth and Breakout Profile ↗

November 04, 2025

Via Chartmill

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

October 28, 2025

From Acadia Pharmaceuticals Inc.

Via Business Wire

Halper Sadeh LLC Encourages Acadia Pharmaceuticals Inc. Shareholders to Contact the Firm to Discuss Their Rights

October 22, 2025

From Halper Sadeh LLC

Via Business Wire

This ACADIA Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗

October 21, 2025

Via Benzinga

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Fits the 'Affordable Growth' Investment Framework ↗

October 21, 2025

Via Chartmill

Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025

October 15, 2025

From Acadia Pharmaceuticals Inc.

Via Business Wire

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Shows Strong Growth and Positive Technical Setup ↗

October 09, 2025

Via Chartmill

Leap Therapeutics (LPTX) Plummets Over 20% Amidst Profit-Taking and Volatility Ahead of Key Clinical Data

October 03, 2025

Via MarketMinute

Acadia Pharmaceuticals Presents Clinical Data from Across Multiple Therapeutic Programs at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®

October 02, 2025

From Acadia Pharmaceuticals Inc.

Via Business Wire

Frequently Asked Questions

Is ACADIA Pharmaceuticals Inc. - Common Stock publicly traded?

Yes, ACADIA Pharmaceuticals Inc. - Common Stock is publicly traded.

What exchange does ACADIA Pharmaceuticals Inc. - Common Stock trade on?

ACADIA Pharmaceuticals Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for ACADIA Pharmaceuticals Inc. - Common Stock?

The ticker symbol for ACADIA Pharmaceuticals Inc. - Common Stock is ACAD on the Nasdaq Stock Market

What is the current price of ACADIA Pharmaceuticals Inc. - Common Stock?

The current price of ACADIA Pharmaceuticals Inc. - Common Stock is 26.49

When was ACADIA Pharmaceuticals Inc. - Common Stock last traded?

The last trade of ACADIA Pharmaceuticals Inc. - Common Stock was at 01/06/26 12:05 PM ET

What is the market capitalization of ACADIA Pharmaceuticals Inc. - Common Stock?

The market capitalization of ACADIA Pharmaceuticals Inc. - Common Stock is 4.31B

How many shares of ACADIA Pharmaceuticals Inc. - Common Stock are outstanding?

ACADIA Pharmaceuticals Inc. - Common Stock has 4B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.